Abbott decides to terminate development of Orion's Simdax in USA

29 April 2007

Finnish drugmaker Orion says that its licensee, US health care major Abbott Laboratories, has decided not to continue the US development program for its intravenously administered drug Simdax (levosimendan), Orion's product for acute decompensated heart failure, because "it would not be commercially reasonable." Accordingly, the considered additional Phase III studies will not be conducted by Abbott, which continues to assess feedback on the agent from discussions with European authorities. Simdax will remain available in already-approved markets.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight